Prosperity Consulting Group LLC Sells 16,959 Shares of Pfizer Inc. (NYSE:PFE)

Prosperity Consulting Group LLC cut its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 22.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 58,574 shares of the biopharmaceutical company's stock after selling 16,959 shares during the quarter. Prosperity Consulting Group LLC's holdings in Pfizer were worth $1,554,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of the business. Passumpsic Savings Bank lifted its holdings in Pfizer by 8.4% in the third quarter. Passumpsic Savings Bank now owns 25,680 shares of the biopharmaceutical company's stock worth $743,000 after buying an additional 1,998 shares during the period. Virtu Financial LLC purchased a new stake in Pfizer in the third quarter worth about $1,499,000. Westside Investment Management Inc. lifted its holdings in Pfizer by 7.7% in the third quarter. Westside Investment Management Inc. now owns 14,008 shares of the biopharmaceutical company's stock worth $404,000 after buying an additional 1,004 shares during the period. Diamant Asset Management Inc. lifted its holdings in Pfizer by 8.4% in the third quarter. Diamant Asset Management Inc. now owns 8,515 shares of the biopharmaceutical company's stock worth $246,000 after buying an additional 660 shares during the period. Finally, Morse Asset Management Inc purchased a new stake in Pfizer in the third quarter worth about $2,649,000. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.75 during trading on Tuesday, hitting $23.80. 98,477,931 shares of the company's stock traded hands, compared to its average volume of 40,819,142. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market capitalization of $134.98 billion, a P/E ratio of 16.88, a PEG ratio of 0.64 and a beta of 0.67. The business has a 50-day simple moving average of $24.52 and a 200-day simple moving average of $25.88.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same quarter in the prior year, the company earned $0.82 earnings per share. Pfizer's revenue was down 7.8% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.23%. The ex-dividend date of this dividend is Friday, May 9th. Pfizer's dividend payout ratio is 121.99%.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.06% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Citigroup reiterated a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price for the company. UBS Group lowered their target price on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a report on Tuesday, April 8th. Finally, The Goldman Sachs Group reiterated a "neutral" rating and set a $25.00 target price (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating, five have given a buy rating and three have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.57.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.